-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
SAB Biotherapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2021 to Q2 2024.
- SAB Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $601K, a 6.73% decline year-over-year.
- SAB Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $2.4M, a 2.42% decline year-over-year.
- SAB Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2.42M, a 9.37% decline from 2022.
- SAB Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.67M, a 15.5% increase from 2021.
- SAB Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.31M, a 78.7% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)